Abstracts

REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR9 AGONIST, AND bNAbs

Background: Various anti-HIV immunotherapy strategies have been associated with ART-free control in non-human primates. We sought to determine whether a combination of such strategies could affect virologic control in people with HIV after ART discontinuation. Methods: We performed a single-arm proof-of-concept study to evaluate the efficacy of a combination approach involving (1) Gag conserved element…

ULTRA-LONG-ACTING BICTEGRAVIR NANOFORMULATIONS

Background: Antiretroviral therapy (ART) halts viral replication leading to reduced morbidity, mortality, and transmission of infection in people living with or at risk for HIV infection. However, therapeutic limitations remain. These include suboptimal adherence, adverse events, regimen tolerability, and viral resistance. To these ends, the need for ultra-long-acting (ULA) antiretroviral (ARV) formulations with extended duration…

OVER- AND UNDER-REPORTING IN HIV TESTING, STATUS, AND TREATMENT IN RURAL SOUTH AFRICA

Background: Surveys are an important source of population-based indicators in tracking the HIV epidemic, including self-reported HIV status, testing history, and treatment adherence. Whether self-reported indicators are accurate has implications for epidemic monitoring but can be challenging to assess, particularly when collected without confirmatory biomarkers. We assess the accuracy of survey indicators by comparing self-reported…

MECHANISM AND RESISTANCE STUDIES OF SARS-CoV-2 MPRO INHIBITOR POMOTRELVIR (PBI-0451)

Background: The unprecedented scale of the COVID-19 pandemic and rapid evolution of SARS-CoV-2 variants underscores the need for broadly active inhibitors with a high barrier to resistance. The coronavirus main protease (Mpro) is an essential viral enzyme required for viral polyprotein processing and is highly conserved across human coronaviruses. Pomotrelvir (PBI-0451) is a novel Mpro…

BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-α2b +3BNC117 & 10-1074 IN CHRONIC HIV INFECTION

Background: BEAT2 (NCT03588715) is an open-label 50-week study in ART-suppressed PLWH undergoing ART substitution with 26 weeks of immunotherapy (IMM-Tx) [pegylated interferon alfa-2b (peg-IFN-α2b) and broadly neutralizing antibodies (bNABs) 3BNC117 and 10-1074], followed by an IMM-Tx free ATI up to 24 weeks. Primary results at week 38 are presented. Methods: Participants had baseline HIV bNAb-sensitive…